The book critically examines the regulation of medicines in Europe, particularly within the EU, highlighting the tension between rapid drug approval for a unified market and the need for democratic accountability. Through extensive research involving interviews with industry stakeholders and regulators, it reveals concerns about the independence of regulatory bodies, the influence of commercial interests on scientific expertise, and the adequacy of drug safety testing and surveillance.
